Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
National Taiwan University Hospital · Asan Medical Center · +25 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
5,832
total citations
- FWCI
- 86.70
- Percentile
- 100%
- References
- 42
Citations per year
Authors
21Topics & keywords
Topics
Keywords
- Sorafenib
- Hepatocellular carcinoma
- Placebo
- Medicine
- Double blind
- Internal medicine
- Phase (matter)
- Oncology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.